Details for New Drug Application (NDA): 212895
✉ Email this page to a colleague
The generic ingredient in CONJUPRI is levamlodipine maleate. One supplier is listed for this compound. Additional details are available on the levamlodipine maleate profile page.
Summary for 212895
Tradename: | CONJUPRI |
Applicant: | Cspc Ouyi |
Ingredient: | levamlodipine maleate |
Patents: | 0 |
Suppliers and Packaging for NDA: 212895
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411 | 24075-0411-3 | 2.5 mg in 1 BOTTLE (24075-0411-3) |
CONJUPRI | levamlodipine maleate | TABLET;ORAL | 212895 | NDA | CSPC Ouyi Pharmaceutical Co. Ltd | 24075-0411 | 24075-0411-5 | 2.5 mg in 1 BOTTLE (24075-0411-5) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 1.25MG BASE | ||||
Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2.5MG BASE | ||||
Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
Approval Date: | Dec 19, 2019 | TE: | RLD: | Yes |
Complete Access Available with Subscription